Literature DB >> 26999019

Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).

Keisuke Izumi, Yuko Kaneko, Misato Hashizume, Keiko Yoshimoto, Tsutomu Takeuchi.   

Abstract

Entities:  

Year:  2016        PMID： 26999019      PMCID： PMC4801414          DOI： 10.1371/journal.pone.0152341

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


× No keyword cloud information.
The x-axis in Panel A within S5 Fig is labeled incorrectly. It should read: 10, 20, 30, 40. Please view the correct S5 Fig below.

Predictive ability of OPN for CDAI remission in patients with RA who received TCZ with concomitant MTX.

(TIF) Click here for additional data file.
  1 in total

1.  Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).

Authors:  Keisuke Izumi; Yuko Kaneko; Misato Hashizume; Keiko Yoshimoto; Tsutomu Takeuchi
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.